- Home
- RDHL vs XTIA Comparison
RDHL vs XTIA Comparison
Compare RDHL & XTIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- XTIA
- Stock Information
- Founded
- RDHL 2009
- XTIA 1999
- Country
- RDHL Israel
- XTIA United States
- Employees
- RDHL N/A
- XTIA N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- XTIA
- Sector
- RDHL Health Care
- XTIA
- Exchange
- RDHL Nasdaq
- XTIA NYSE
- Market Cap
- RDHL 8.6M
- XTIA 9.7M
- IPO Year
- RDHL N/A
- XTIA N/A
- Fundamental
- Price
- RDHL $6.99
- XTIA $0.05
- Analyst Decision
- RDHL
- XTIA
- Analyst Count
- RDHL 0
- XTIA 0
- Target Price
- RDHL N/A
- XTIA N/A
- AVG Volume (30 Days)
- RDHL 21.2K
- XTIA 81.6M
- Earning Date
- RDHL 12-27-2024
- XTIA 11-14-2024
- Dividend Yield
- RDHL N/A
- XTIA N/A
- EPS Growth
- RDHL N/A
- XTIA N/A
- EPS
- RDHL N/A
- XTIA N/A
- Revenue
- RDHL $3,707,000.00
- XTIA $2,169,000.00
- Revenue This Year
- RDHL $224.90
- XTIA N/A
- Revenue Next Year
- RDHL $82.69
- XTIA N/A
- P/E Ratio
- RDHL N/A
- XTIA N/A
- Revenue Growth
- RDHL N/A
- XTIA N/A
- 52 Week Low
- RDHL $6.35
- XTIA $0.04
- 52 Week High
- RDHL $43.50
- XTIA $8.00
- Technical
- Relative Strength Index (RSI)
- RDHL 42.91
- XTIA 37.61
- Support Level
- RDHL $7.09
- XTIA $0.04
- Resistance Level
- RDHL $7.44
- XTIA $0.05
- Average True Range (ATR)
- RDHL 0.53
- XTIA 0.01
- MACD
- RDHL -0.03
- XTIA 0.00
- Stochastic Oscillator
- RDHL 12.36
- XTIA 31.58
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About XTIA XTI AEROSPACE
XTI Aerospace Inc is a development-stage aircraft manufacturer. XTI is developing a vertical takeoff and landing (VTOL) aircraft, the TriFan 600, which is a design-stage six-passenger aircraft that it anticipates will provide point-to-point air travel over distances of up to 700 miles while significantly reducing carbon emissions per mile compared to today's gasoline-powered jet aircraft and helicopters. The TriFan 600 is expected to have a wide usage ranging from private and commercial aviation services for businesses and high-net-worth individuals to emergency medical services (EMS). The Company's operations are located primarily in the United States, Germany, and the United Kingdom.